Immunotherapy combo shows promise in first-line lung cancer trial
Shares in Australian immunotherapy specialist Immutep (ASX: IMM) are up 15% after news of a positive clinical trial result in lung cancer. The company is working on novel LAG-3 immunotherapies for cancer and autoimmune disease, including lead candidate eftilagimod alpha. Results from the Phase II TACTI-002 trial show the potential of its first-in-class MHC Class … [Read more…]